Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics (Nasdaq: SLN) reported Q3 2025 results and business updates on November 6, 2025. Key highlights include completion of SANRECO Phase 2 enrollment for divesiran in polycythemia vera (48 phlebotomy-dependent patients) and anticipation of topline results in 3Q 2026. The company reported $102.2 million in cash, cash equivalents and short-term investments as of September 30, 2025, which management expects will fund operations into 2028. Q3 operating figures: R&D $20.5M, G&A $5.8M (down $1.9M YoY), and net loss $21.0M (improved from $35.5M a year earlier).

Silence Therapeutics (Nasdaq: SLN) completed enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera (PV).

The global, randomized, double-blind, placebo-controlled study enrolled 48 phlebotomy-dependent PV patients. The primary endpoint is the proportion maintaining hematocrit <45% without phlebotomies between weeks 18 and 36. Secondary endpoints include safety, pharmacokinetics, and quality of life. Topline results are anticipated in 3Q 2026. The Phase 2 design incorporates a 12-week dosing interval informed by Phase 1 data showing durable HCT control with infrequent dosing.

Silence Therapeutics (NASDAQ:SLN), a clinical-stage biotechnology company focused on developing siRNA therapies, has announced its participation in two upcoming investor conferences in September 2025.

Management will present at the Morgan Stanley Global Healthcare Conference on September 9 at 5:35 p.m. ET and the H.C. Wainwright Global Investment Conference on September 10 at 12:00 p.m. ET. Both presentations will be available via webcast through the company's investor relations website.

Silence Therapeutics (NASDAQ:SLN) reported Q2 2025 financial results and clinical progress. The company presented encouraging SANRECO Phase 1 data for divesiran in Polycythemia Vera (PV) at EHA 2025, demonstrating durable hematocrit control and elimination of phlebotomy needs. The Phase 2 SANRECO trial has surpassed 50% enrollment and remains on track for completion by year-end 2025.

Financial highlights include $114.2 million in cash and investments, providing runway into 2028. Q2 2025 saw R&D expenses of $17.6 million (up from $13.8M in Q2 2024) and G&A expenses of $5.1 million (down from $7.0M). Net loss widened to $27.4 million compared to $19.8M in Q2 2024.

The company completed Phase 3 readiness activities for zerlasiran in cardiovascular disease and is pursuing partnership discussions. Silence has paused the Phase 1 study of SLN548 to prioritize promising extra-hepatic cell targeting research.

Silence Therapeutics (SLN) reported its Q1 2025 financial results and business updates. The company ended Q1 with $136.5 million in cash and investments, down from $147.3 million in Q4 2024. Net loss widened to $28.5 million ($0.20 per share) compared to $2.3 million ($0.02 per share) in Q1 2024. R&D expenses increased by $9.0 million to $20.8 million, while G&A expenses rose by $1.0 million to $7.7 million. The company is implementing cost-saving measures to extend its cash runway into 2028. Key developments include advancing the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), with enrollment completion expected by end-2025. Additional Phase 1 results will be presented at EHA 2025. The company is also progressing with Phase 3 readiness activities for zerlasiran in cardiovascular disease.

Silence Therapeutics (NASDAQ: SLN), a clinical-stage company developing siRNA therapies, has appointed Tim McInerney to its Board of Directors. McInerney brings over 30 years of pharmaceutical and biotechnology experience, including significant roles in early-stage financings of companies like Cougar Biotech and Kite Pharma. He previously served as chairman of Insite Vision and led the Special Committee in Emisphere Technologies' $1.8 billion sale to Novo Nordisk.

The company also announced that James Ede-Golightly will retire from the Board at the June 2025 AGM after serving since 2019. Ede-Golightly played a crucial role in Silence's evolution, including its delisting from the London Stock Exchange and transition to becoming a Nasdaq-listed U.S. domestic issuer.

Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company specializing in siRNA therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company's management will deliver a corporate overview presentation on Wednesday, March 12th at 1:00 p.m. ET.

Interested parties can access the live webcast through the Investors section of Silence's website at www.silence-therapeutics.com. A recorded version of the presentation will be made available for later viewing after the conference concludes.

Silence Therapeutics (SLN) reported its full year 2024 financial results, ending with $147.3 million in cash and investments. The company's collaboration revenue increased to $43.1 million from $30.9 million in 2023, while net loss improved to $45.3 million ($0.33 per share) from $54.2 million in 2023.

Key developments include: positive regulatory feedback for zerlasiran's Phase 3 study design, though initiation depends on securing a partnership; anticipated full enrollment in divesiran's SANRECO Phase 2 study for PV by end of 2025; and planned Phase 1 studies for SLN548 in H2 2025. R&D expenses increased to $67.9 million from $56.9 million, while G&A expenses slightly rose to $26.9 million.

The company has extended its cash guidance into 2027, focusing on rare condition treatments where they can deliver first-in-class and/or best-in-class siRNAs.